乳癌チューブリン阻害剤の世界市場:規模・現状・予測2019-2025

QYResearchが発行した調査報告書(QYR20FB13738)
◆英語タイトル:Global Tubulin Inhibitors for Breast Cancer Market Size, Status and Forecast 2019-2025
◆商品コード:QYR20FB13738
◆発行会社(リサーチ会社):QYResearch
◆発行日:2019年11月18日(※2024年版があります。お問い合わせください。)
◆ページ数:134
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

※当調査レポートでは、乳癌チューブリン阻害剤の世界市場について調査・分析し、乳癌チューブリン阻害剤の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別(エリブリン、イキサベピロン、ドセタキセル、トラスツズマブエムタンシン、ウチデロン、パクリタキセル、リポソームパクリタキセル、タンパク質結合パクリタキセル)、用途別(病院、診療所、医薬品センター、その他)、地域別(北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米)に区分して市場規模を算出しました。


・レポートの概要
・世界の乳癌チューブリン阻害剤市場動向
・主要企業別マーケットシェア
・乳癌チューブリン阻害剤の種類別市場規模2014-2019
(エリブリン、イキサベピロン、ドセタキセル、トラスツズマブエムタンシン、ウチデロン、パクリタキセル、リポソームパクリタキセル、タンパク質結合パクリタキセル)
・乳癌チューブリン阻害剤の用途別市場規模2014-2019
(病院、診療所、医薬品センター、その他)
・乳癌チューブリン阻害剤の北米市場:主要企業・種類別/用途別市場規模
・乳癌チューブリン阻害剤のヨーロッパ市場:主要企業・種類別/用途別市場規模
・乳癌チューブリン阻害剤の中国市場:主要企業・種類別/用途別市場規模
・乳癌チューブリン阻害剤の日本国内市場:主要企業・種類別/用途別市場規模
・乳癌チューブリン阻害剤の東南アジア市場:主要企業・種類別/用途別市場規模
・乳癌チューブリン阻害剤のインド市場:主要企業・種類別/用途別市場規模
・乳癌チューブリン阻害剤の中南米市場:主要企業・種類別/用途別市場規模
・主要企業のプロフィール
(Eisai、Bristol-Myers Squibb、Otsuka Pharmaceutical、Hengrui Medicine、Sanofi、Qilu Pharma、Shenzhen Main Luck Pharma、Jiangsu Aosaikang Pharma、Genentech、Beijing Biostar Technologies、Celgene Corporation、Hospira、Biological E.、Taj Accura、Khandelwal Laboratories、Luye Pharma、Beijing Youcare、Beijing Union、Haiyao、Chuntch、CSPC Pharmaceutical、Aosaikang Pharm)
・乳癌チューブリン阻害剤の市場規模予測2019-2025
(種類別、用途別、地域別市場予測)
・アナリストの観点・結論
...
【レポートの概要】

In 2018, the global Tubulin Inhibitors for Breast Cancer market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Tubulin Inhibitors for Breast Cancer status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Tubulin Inhibitors for Breast Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study
Eisai
Bristol-Myers Squibb
Otsuka Pharmaceutical
Hengrui Medicine
Sanofi
Qilu Pharma
Shenzhen Main Luck Pharma
Jiangsu Aosaikang Pharma
Genentech
Beijing Biostar Technologies
Celgene Corporation
Hospira
Biological E.
Taj Accura
Khandelwal Laboratories
Luye Pharma
Beijing Youcare
Beijing Union
Haiyao
Chuntch
CSPC Pharmaceutical
Aosaikang Pharm

Market segment by Type, the product can be split into
Eribulin
Ixabepilone
Docetaxel
Trastuzumab Emtansine
Utidelone
Paclitaxel
Liposome Paclitaxel
Protein-bound Paclitaxel

Market segment by Application, split into
Hospital
Clinic
Drug Center
Other

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Tubulin Inhibitors for Breast Cancer status, future forecast, growth opportunity, key market and key players.
To present the Tubulin Inhibitors for Breast Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Tubulin Inhibitors for Breast Cancer are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

【レポートの目次】

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Tubulin Inhibitors for Breast Cancer Market Size Growth Rate by Type (2014-2025)
1.4.2 Eribulin
1.4.3 Ixabepilone
1.4.4 Docetaxel
1.4.5 Trastuzumab Emtansine
1.4.6 Utidelone
1.4.7 Paclitaxel
1.4.8 Liposome Paclitaxel
1.4.9 Protein-bound Paclitaxel
1.5 Market by Application
1.5.1 Global Tubulin Inhibitors for Breast Cancer Market Share by Application (2019-2025)
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Drug Center
1.5.5 Other
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Tubulin Inhibitors for Breast Cancer Market Size
2.2 Tubulin Inhibitors for Breast Cancer Growth Trends by Regions
2.2.1 Tubulin Inhibitors for Breast Cancer Market Size by Regions (2019-2025)
2.2.2 Tubulin Inhibitors for Breast Cancer Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players
3.1 Tubulin Inhibitors for Breast Cancer Market Size by by Players
3.1.1 Global Tubulin Inhibitors for Breast Cancer Revenue by by Players (2014-2019)
3.1.2 Global Tubulin Inhibitors for Breast Cancer Revenue Market Share by by Players (2014-2019)
3.1.3 Global Tubulin Inhibitors for Breast Cancer Market Concentration Ratio (CR5 and HHI)
3.2 Tubulin Inhibitors for Breast Cancer Key Players Head office and Area Served
3.3 Key Players Tubulin Inhibitors for Breast Cancer Product/Solution/Service
3.4 Date of Enter into Tubulin Inhibitors for Breast Cancer Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Tubulin Inhibitors for Breast Cancer Market Size by Type (2014-2019)
4.2 Global Tubulin Inhibitors for Breast Cancer Market Size by Application (2014-2019)

5 North America
5.1 North America Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
5.2 Tubulin Inhibitors for Breast Cancer Key Players in North America
5.3 North America Tubulin Inhibitors for Breast Cancer Market Size by Type
5.4 North America Tubulin Inhibitors for Breast Cancer Market Size by Application

6 Europe
6.1 Europe Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
6.2 Tubulin Inhibitors for Breast Cancer Key Players in Europe
6.3 Europe Tubulin Inhibitors for Breast Cancer Market Size by Type
6.4 Europe Tubulin Inhibitors for Breast Cancer Market Size by Application

7 China
7.1 China Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
7.2 Tubulin Inhibitors for Breast Cancer Key Players in China
7.3 China Tubulin Inhibitors for Breast Cancer Market Size by Type
7.4 China Tubulin Inhibitors for Breast Cancer Market Size by Application

8 Japan
8.1 Japan Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
8.2 Tubulin Inhibitors for Breast Cancer Key Players in Japan
8.3 Japan Tubulin Inhibitors for Breast Cancer Market Size by Type
8.4 Japan Tubulin Inhibitors for Breast Cancer Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
9.2 Tubulin Inhibitors for Breast Cancer Key Players in Southeast Asia
9.3 Southeast Asia Tubulin Inhibitors for Breast Cancer Market Size by Type
9.4 Southeast Asia Tubulin Inhibitors for Breast Cancer Market Size by Application

10 India
10.1 India Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
10.2 Tubulin Inhibitors for Breast Cancer Key Players in India
10.3 India Tubulin Inhibitors for Breast Cancer Market Size by Type
10.4 India Tubulin Inhibitors for Breast Cancer Market Size by Application

11 Central & South America
11.1 Central & South America Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
11.2 Tubulin Inhibitors for Breast Cancer Key Players in Central & South America
11.3 Central & South America Tubulin Inhibitors for Breast Cancer Market Size by Type
11.4 Central & South America Tubulin Inhibitors for Breast Cancer Market Size by Application

12 International Players Profiles
12.1 Eisai
12.1.1 Eisai Company Details
12.1.2 Company Description and Business Overview
12.1.3 Tubulin Inhibitors for Breast Cancer Introduction
12.1.4 Eisai Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019))
12.1.5 Eisai Recent Development
12.2 Bristol-Myers Squibb
12.2.1 Bristol-Myers Squibb Company Details
12.2.2 Company Description and Business Overview
12.2.3 Tubulin Inhibitors for Breast Cancer Introduction
12.2.4 Bristol-Myers Squibb Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
12.2.5 Bristol-Myers Squibb Recent Development
12.3 Otsuka Pharmaceutical
12.3.1 Otsuka Pharmaceutical Company Details
12.3.2 Company Description and Business Overview
12.3.3 Tubulin Inhibitors for Breast Cancer Introduction
12.3.4 Otsuka Pharmaceutical Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
12.3.5 Otsuka Pharmaceutical Recent Development
12.4 Hengrui Medicine
12.4.1 Hengrui Medicine Company Details
12.4.2 Company Description and Business Overview
12.4.3 Tubulin Inhibitors for Breast Cancer Introduction
12.4.4 Hengrui Medicine Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
12.4.5 Hengrui Medicine Recent Development
12.5 Sanofi
12.5.1 Sanofi Company Details
12.5.2 Company Description and Business Overview
12.5.3 Tubulin Inhibitors for Breast Cancer Introduction
12.5.4 Sanofi Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
12.5.5 Sanofi Recent Development
12.6 Qilu Pharma
12.6.1 Qilu Pharma Company Details
12.6.2 Company Description and Business Overview
12.6.3 Tubulin Inhibitors for Breast Cancer Introduction
12.6.4 Qilu Pharma Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
12.6.5 Qilu Pharma Recent Development
12.7 Shenzhen Main Luck Pharma
12.7.1 Shenzhen Main Luck Pharma Company Details
12.7.2 Company Description and Business Overview
12.7.3 Tubulin Inhibitors for Breast Cancer Introduction
12.7.4 Shenzhen Main Luck Pharma Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
12.7.5 Shenzhen Main Luck Pharma Recent Development
12.8 Jiangsu Aosaikang Pharma
12.8.1 Jiangsu Aosaikang Pharma Company Details
12.8.2 Company Description and Business Overview
12.8.3 Tubulin Inhibitors for Breast Cancer Introduction
12.8.4 Jiangsu Aosaikang Pharma Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
12.8.5 Jiangsu Aosaikang Pharma Recent Development
12.9 Genentech
12.9.1 Genentech Company Details
12.9.2 Company Description and Business Overview
12.9.3 Tubulin Inhibitors for Breast Cancer Introduction
12.9.4 Genentech Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
12.9.5 Genentech Recent Development
12.10 Beijing Biostar Technologies
12.10.1 Beijing Biostar Technologies Company Details
12.10.2 Company Description and Business Overview
12.10.3 Tubulin Inhibitors for Breast Cancer Introduction
12.10.4 Beijing Biostar Technologies Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
12.10.5 Beijing Biostar Technologies Recent Development
12.11 Celgene Corporation
12.12 Hospira
12.13 Biological E.
12.14 Taj Accura
12.15 Khandelwal Laboratories
12.16 Luye Pharma
12.17 Beijing Youcare
12.18 Beijing Union
12.19 Haiyao
12.20 Chuntch
12.21 CSPC Pharmaceutical
12.22 Aosaikang Pharm

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Product (2019-2025)
13.2 Market Size Forecast by Application (2019-2025)
13.3 Market Size Forecast by Regions
13.4 North America
13.5 Europe
13.6 China
13.7 Japan
13.8 Southeast Asia
13.9 India
13.10 Central & South America

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details

...

【掲載企業】

Eisai、Bristol-Myers Squibb、Otsuka Pharmaceutical、Hengrui Medicine、Sanofi、Qilu Pharma、Shenzhen Main Luck Pharma、Jiangsu Aosaikang Pharma、Genentech、Beijing Biostar Technologies、Celgene Corporation、Hospira、Biological E.、Taj Accura、Khandelwal Laboratories、Luye Pharma、Beijing Youcare、Beijing Union、Haiyao、Chuntch、CSPC Pharmaceutical、Aosaikang Pharm

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 乳癌チューブリン阻害剤の世界市場:規模・現状・予測2019-2025(Global Tubulin Inhibitors for Breast Cancer Market Size, Status and Forecast 2019-2025)]についてメールでお問い合わせはこちらでお願いします。